DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+3.45%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.35B
AUM Growth
+$3.35B
(-3.7%)
Cap. Flow
-$548M
Cap. Flow
% of AUM
-16.37%
Top 10 Holdings %
Top 10 Hldgs %
41.71%
Holding
75
New
10
Increased
22
Reduced
20
Closed
8
Top Buys
| 1 |
Immunovant
IMVT
|
$63.1M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$57.5M |
| 3 |
TG Therapeutics
TGTX
|
$51.1M |
| 4 |
Axsome Therapeutics
AXSM
|
$44.1M |
| 5 |
argenx
ARGX
|
$43M |
Top Sells
| 1 |
Insmed
INSM
|
$187M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$80.8M |
| 3 |
Geron
GERN
|
$74.2M |
| 4 |
Apogee Therapeutics
APGE
|
$52.1M |
| 5 |
Guardant Health
GH
|
$43.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Invivyd
IVVD
$218M
| $12M | 0.36% |
10,953,937
| – | – |
|
52
Zura Bio
ZURA
$132M
| $11.5M | 0.34% |
3,283,783
+760,783
| +30% | +$2.66M |
|
53
Kura Oncology
KURA
$732M
| $7.92M | 0.24% |
+384,756
| New | +$7.92M |
|
54
Cytokinetics
CYTK
$5.98B
| $7.18M | 0.21% |
+132,495
| New | +$7.18M |
|
|
RGLS
55
DELISTED
Regulus Therapeutics
RGLS
| $5.82M | 0.17% |
3,262,564
-4,002
| -0.1% | -$7.14K |
|
56
Alto Neuroscience
ANRO
$97.7M
| $5.47M | 0.16% |
511,686
-88,314
| -15% | -$944K |
|
|
AGEN
57
Agenus
AGEN
$136M
| $5.25M | 0.16% |
313,359
-1,271,518
| -80% | -$21.3M |
|
|
ALLK
58
DELISTED
Allakos
ALLK
| $5M | 0.15% |
5,000,000
| – | – |
|
|
SYRS
59
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4.27M | 0.13% |
828,485
| – | – |
|
60
Relmada Therapeutics
RLMD
$48.8M
| $3.7M | 0.11% |
1,234,773
-5,261
| -0.4% | -$15.8K |
|
61
Edgewise Therapeutics
EWTX
$1.54B
| $3.36M | 0.1% |
+186,386
| New | +$3.36M |
|
62
Scholar Rock
SRRK
$3.3B
| $3.1M | 0.09% |
372,559
-307,441
| -45% | -$2.56M |
|
63
Repare Therapeutics
RPTX
$73.9M
| $2.98M | 0.09% |
904,261
-1,780,083
| -66% | -$5.87M |
|
64
Cogent Biosciences
COGT
$1.83B
| $2.6M | 0.08% |
308,235
-7,765
| -2% | -$65.5K |
|
|
VIGL
65
DELISTED
Vigil Neuroscience
VIGL
| $2.39M | 0.07% |
597,215
-997,716
| -63% | -$3.99M |
|
66
Aligos Therapeutics
ALGS
$75.1M
| $2.14M | 0.06% |
244,111
| – | – |
|
67
Metagenomi
MGX
$67.2M
| $1.9M | 0.06% |
466,232
| – | – |
|
68
AnaptysBio
ANAB
$630M
| – | – |
-529,452
| Closed | -$11.9M |
|
69
Mersana Therapeutics
MRSN
$34.8M
| – | – |
-23,187
| Closed | -$2.6M |
|
70
Neumora Therapeutics
NMRA
$283M
| – | – |
-1,000,000
| Closed | -$13.8M |
|
71
Nuvalent
NUVL
$5.74B
| – | – |
-274,512
| Closed | -$20.6M |
|
72
Pacific Biosciences
PACB
$378M
| – | – |
-7,000,000
| Closed | -$26.3M |
|
73
Prime Medicine
PRME
$595M
| – | – |
-303,716
| Closed | -$2.13M |
|
74
Ultragenyx Pharmaceutical
RARE
$3.04B
| – | – |
-167,784
| Closed | -$7.83M |
|
75
Tourmaline Bio
TRML
$645M
| – | – |
-1,595,400
| Closed | -$36.5M |
|